Hudson Bay Capital Management
SMMT icon

Hudson Bay Capital Management’s Summit Therapeutics SMMT Stock Holding History

Hudson Bay Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,440
Closed -$200K – 1578
2025
Q4 		$200K Buy
+11,440
New +$215K ﹤0.01% 970
2024
Q3 		– Sell
-75,000
Closed -$585K – 1021
2024
Q2 		$585K Buy
+75,000
New +$405K ﹤0.01% 637

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hudson Bay Capital Management's SMMT Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 11,440 shares — an estimated $200K sold.

Hudson Bay Capital Management first reported a position in SMMT in Q2 2024 and held it in 2 quarters. The position peaked at $585K in Q2 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 11,440 Summit Therapeutics shares in Q1 2026, an estimated $200K.
  • Hudson Bay Capital Management first reported a position in Summit Therapeutics in Q2 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's Summit Therapeutics position peaked at $585K in Q2 2024.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.